---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014253"
form_type: "8-K"
ticker: "PALI"
cik: "0001357459"
company_name: "PALISADE BIO, INC."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:18:56.995680+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Palisade Bio details PALI-2108 development for ulcerative colitis at IBD conference

## Summary
- PALI-2108 is a colon-specific PDE4 inhibitor prodrug for moderate-to-severe ulcerative colitis.
- Phase 1 clinical study planned to begin before year-end 2024.
- Development supported by $500,000 research agreement with Giiant from the Crohn's & Colitis Foundation.
- Presentation given at IBD Innovate in Cambridge, MA on April 9-10, 2024.

## SEC filing metadata
- accession: 0001493152-24-014253
- form_type: 8-K
- ticker: PALI
- cik: 0001357459
- company_name: PALISADE BIO, INC.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357459/000149315224014253/0001493152-24-014253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357459/000149315224014253/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014253
- JSON: https://secwatch.observer/filing/0001493152-24-014253.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014253.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.